Another unexpected finding was that ADAM12 serum levels did not associate with mesenchymal subtype (CMS4) tumors in the CAIRO2 cohort using the IHC-classifier, nor with tumor budding [37, 39, 52] Both features are at least in part tumor cell-intrinsic but are also suspected to associate with increased stromal content and activation, respectively. The gene discussed is ADAM12; the disease is neoplasm.